The Experts below are selected from a list of 801 Experts worldwide ranked by ideXlab platform
Soolingen D. Van - One of the best experts on this subject based on the ideXlab platform.
-
Synergistic activity of rifampicin and ethambutol against slow-growing nontuberculous mycobacteria is currently of questionable clinical significance
2013Co-Authors: Ingen, J. Van, Boeree M.j., Hoefsloot W., Mouton J.w., Soolingen D. VanAbstract:A key issue in the treatment of disease caused by slow-growing nontuberculous mycobacteria is the limited association between in vitro minimum inhibitory concentrations (MICs) of rifampicin and ethambutol alone and the in vivo outcome of treatment with these drugs. Combined susceptibility testing to rifampicin and ethambutol could provide a more realistic view of the efficacy of these drugs. In this study, Mycobacterium avium (n=5), Mycobacterium chimaera (n=6), Mycobacterium intracellulare (n=4), Mycobacterium xenopi (n=4), Mycobacterium malmoense (n=3) and Mycobacterium simiae (n=2) clinical isolates were selected and the MICs of rifampicin and ethambutol alone and in combination were measured using the Middlebrook 7H10 agar dilution method. Synergy was defined as a fractional inhibitory concentration index
-
Synergistic activity of rifampicin and ethambutol against slow-growing nontuberculous mycobacteria is currently of questionable clinical significance
'Elsevier BV', 2013Co-Authors: Ingen, J. Van, Boeree M.j., Hoefsloot W., Mouton † J.w., Soolingen D. VanAbstract:Contains fulltext : 117716.pdf (Publisher’s version ) (Closed access)A key issue in the treatment of disease caused by slow-growing nontuberculous mycobacteria is the limited association between in vitro minimum inhibitory concentrations (MICs) of rifampicin and ethambutol alone and the in vivo outcome of treatment with these drugs. Combined susceptibility testing to rifampicin and ethambutol could provide a more realistic view of the efficacy of these drugs. In this study, Mycobacterium avium (n=5), Mycobacterium chimaera (n=6), Mycobacterium intracellulare (n=4), Mycobacterium xenopi (n=4), Mycobacterium malmoense (n=3) and Mycobacterium simiae (n=2) clinical isolates were selected and the MICs of rifampicin and ethambutol alone and in combination were measured using the Middlebrook 7H10 agar dilution method. Synergy was defined as a fractional inhibitory concentration index
-
Complete genome sequence of Mycobacterium xenopi type strain RIVM700367.
2012Co-Authors: Abdallah A.m., Soolingen D. Van, Rashid M., Adroub S.a., Elabdalaoui H., Ali S., Bitter W., Pain A.Abstract:Mycobacterium xenopi is a slow-growing, thermophilic, water-related Mycobacterium species. Like other nontuberculous mycobacteria, M. xenopi more commonly infects humans with altered immune function, such as chronic obstructive pulmonary disease patients. It is considered clinically relevant in a significant proportion of the patients from whom it is isolated. We report here the whole genome sequence of M. xenopi type strain RIVM700367
-
Complete genome sequence of Mycobacterium xenopi type strain RIVM700367.
'American Society for Microbiology', 2012Co-Authors: Abdallah A.m., Soolingen D. Van, Rashid M., Adroub S.a., Elabdalaoui H., Ali S., Bitter W., Pain A.Abstract:Item does not contain fulltextMycobacterium xenopi is a slow-growing, thermophilic, water-related Mycobacterium species. Like other nontuberculous mycobacteria, M. xenopi more commonly infects humans with altered immune function, such as chronic obstructive pulmonary disease patients. It is considered clinically relevant in a significant proportion of the patients from whom it is isolated. We report here the whole genome sequence of M. xenopi type strain RIVM700367.1 juni 201
-
In vitro drug susceptibility of 2275 clinical non-tuberculous Mycobacterium isolates of 49 species in The Netherlands.
'Elsevier BV', 2010Co-Authors: Ingen, J. Van, Boeree M.j., Dekhuijzen R., Laan T. Van Der, Soolingen D. VanAbstract:Contains fulltext : 88100.pdf (publisher's version ) (Closed access)In this study, 2275 clinical isolates of 49 species of non-tuberculous mycobacteria isolated in The Netherlands were subjected to standardised drug susceptibility testing using the Middlebrook 7H10 agar dilution method. Clarithromycin and rifabutin were most active, with 87% and 83% of all isolates, respectively, being susceptible. Susceptibility to ciprofloxacin (44%) and amikacin (32%) was limited and was mostly restricted to Mycobacterium kansasii, Mycobacterium xenopi, Mycobacterium fortuitum and phylogenetically related species. Susceptibility to isoniazid (0.5%), rifampicin (37%), ethambutol (35%) and streptomycin (33%) was rare; susceptibility to cycloserine, clofazimine and prothionamide was generally restricted to slow growers, although prothionamide also had activity against M. fortuitum and related species. Significant discrepancies between in vitro and in vivo activity exist. To improve the utility of drug susceptibility testing, the selection of drugs should be changed to more drugs with proven clinical efficacy correlating with in vitro susceptibility.1 februari 201
Richard J Wallace - One of the best experts on this subject based on the ideXlab platform.
-
treatment of nontuberculous mycobacterial pulmonary disease an official ats ers escmid idsa clinical practice guideline
Clinical Infectious Diseases, 2020Co-Authors: Charles L Daley, Richard J Wallace, Jonathan M Iaccarino, Christoph Lange, Emmanuelle Cambau, Claire Andrejak, Erik C Bottger, Jan Brozek, David E Griffith, Lorenzo GuglielmettiAbstract:Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (without cystic fibrosis or human immunodeficiency virus infection) caused by the most common NTM pathogens such as Mycobacterium avium complex, Mycobacterium kansasii, and Mycobacterium xenopi among the slowly growing NTM and Mycobacterium abscessus among the rapidly growing NTM. A panel of experts was carefully selected by leading international respiratory medicine and infectious diseases societies (ATS, ERS, ESCMID, IDSA) and included specialists in pulmonary medicine, infectious diseases and clinical microbiology, laboratory medicine, and patient advocacy. Systematic reviews were conducted around each of 22 PICO (Population, Intervention, Comparator, Outcome) questions and the recommendations were formulated, written, and graded using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. Thirty-one evidence-based recommendations about treatment of NTM pulmonary disease are provided. This guideline is intended for use by healthcare professionals who care for patients with NTM pulmonary disease, including specialists in infectious diseases and pulmonary diseases.
-
treatment of nontuberculous mycobacterial pulmonary disease an official ats ers escmid idsa clinical practice guideline executive summary
Clinical Infectious Diseases, 2020Co-Authors: Charles L Daley, Richard J Wallace, Jonathan M Iaccarino, Christoph Lange, Emmanuelle Cambau, Claire Andrejak, Erik C Bottger, Jan Brozek, David E Griffith, Lorenzo GuglielmettiAbstract:Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (without cystic fibrosis or human immunodeficiency virus infection) caused by the most common NTM pathogens such as Mycobacterium avium complex, Mycobacterium kansasii, and Mycobacterium xenopi among the slowly growing NTM and Mycobacterium abscessus among the rapidly growing NTM. A panel of experts was carefully selected by leading international respiratory medicine and infectious diseases societies (ATS, ERS, ESCMID, IDSA) and included specialists in pulmonary medicine, infectious diseases and clinical microbiology, laboratory medicine, and patient advocacy. Systematic reviews were conducted around each of 22 PICO (Population, Intervention, Comparator, Outcome) questions and the recommendations were formulated, written, and graded using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. Thirty-one evidence-based recommendations about treatment of NTM pulmonary disease are provided. This guideline is intended for use by healthcare professionals who care for patients with NTM pulmonary disease, including specialists in infectious diseases and pulmonary diseases.
-
in vitro activity of linezolid against slowly growing nontuberculous mycobacteria
Antimicrobial Agents and Chemotherapy, 2003Co-Authors: Barbara A Brownelliott, Christopher J Crist, Linda Mann, Rebecca W Wilson, Richard J WallaceAbstract:MICs of linezolid in broth microdilutions were tested against 341 slowly growing nontuberculous mycobacteria (NTM) belonging to 15 species. The proposed linezolid susceptibility MICs for all Mycobacterium marinum, Mycobacterium szulgai, Mycobacterium kansasii, Mycobacterium malmoense, and Mycobacterium xenopi isolates and for 90% of Mycobacterium gordonae and Mycobacterium triplex isolates were ≤8 μg/ml. Linezolid has excellent therapeutic potential against most species of NTM.
Lorenzo Guglielmetti - One of the best experts on this subject based on the ideXlab platform.
-
treatment of nontuberculous mycobacterial pulmonary disease an official ats ers escmid idsa clinical practice guideline executive summary
Clinical Infectious Diseases, 2020Co-Authors: Charles L Daley, Richard J Wallace, Jonathan M Iaccarino, Christoph Lange, Emmanuelle Cambau, Claire Andrejak, Erik C Bottger, Jan Brozek, David E Griffith, Lorenzo GuglielmettiAbstract:Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (without cystic fibrosis or human immunodeficiency virus infection) caused by the most common NTM pathogens such as Mycobacterium avium complex, Mycobacterium kansasii, and Mycobacterium xenopi among the slowly growing NTM and Mycobacterium abscessus among the rapidly growing NTM. A panel of experts was carefully selected by leading international respiratory medicine and infectious diseases societies (ATS, ERS, ESCMID, IDSA) and included specialists in pulmonary medicine, infectious diseases and clinical microbiology, laboratory medicine, and patient advocacy. Systematic reviews were conducted around each of 22 PICO (Population, Intervention, Comparator, Outcome) questions and the recommendations were formulated, written, and graded using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. Thirty-one evidence-based recommendations about treatment of NTM pulmonary disease are provided. This guideline is intended for use by healthcare professionals who care for patients with NTM pulmonary disease, including specialists in infectious diseases and pulmonary diseases.
-
treatment of nontuberculous mycobacterial pulmonary disease an official ats ers escmid idsa clinical practice guideline
Clinical Infectious Diseases, 2020Co-Authors: Charles L Daley, Richard J Wallace, Jonathan M Iaccarino, Christoph Lange, Emmanuelle Cambau, Claire Andrejak, Erik C Bottger, Jan Brozek, David E Griffith, Lorenzo GuglielmettiAbstract:Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (without cystic fibrosis or human immunodeficiency virus infection) caused by the most common NTM pathogens such as Mycobacterium avium complex, Mycobacterium kansasii, and Mycobacterium xenopi among the slowly growing NTM and Mycobacterium abscessus among the rapidly growing NTM. A panel of experts was carefully selected by leading international respiratory medicine and infectious diseases societies (ATS, ERS, ESCMID, IDSA) and included specialists in pulmonary medicine, infectious diseases and clinical microbiology, laboratory medicine, and patient advocacy. Systematic reviews were conducted around each of 22 PICO (Population, Intervention, Comparator, Outcome) questions and the recommendations were formulated, written, and graded using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. Thirty-one evidence-based recommendations about treatment of NTM pulmonary disease are provided. This guideline is intended for use by healthcare professionals who care for patients with NTM pulmonary disease, including specialists in infectious diseases and pulmonary diseases.
Steffen Nock - One of the best experts on this subject based on the ideXlab platform.
-
establishment of intein mediated protein ligation under denaturing conditions c terminal labeling of a single chain antibody for biochip screening
Bioconjugate Chemistry, 2002Co-Authors: Jens Sydor, Steve Sideris, Maria Mariano, Steffen NockAbstract:Intein-mediated protein ligation is a recently developed method that enables the C-terminal labeling of proteins. This technique requires a correctly folded intein mutant that is fused to the C-terminus of a target protein to create a thioester, which allows the ligation of a peptide with an N-terminal cysteine (1, 2). Here we describe the establishment of this method for the labeling, under denaturing conditions, of target proteins that are expressed insolubly as intein fusion proteins. A GFPuv fusion protein with the Mycobacterium xenopi gyrA intein was expressed in inclusion bodies in Escherichia coli and initially used as a model protein to verify intein cleavage activity under different refolding conditions. The intein showed activity after refolding in nondenaturing and slightly denaturing conditions. A construct of the same intein with an anti-neutravidin single-chain antibody was also expressed in an insoluble form. The intein-mediated ligation was established for this single chain antibody−intein...
-
establishment of intein mediated protein ligation under denaturing conditions c terminal labeling of a single chain antibody for biochip screening
Bioconjugate Chemistry, 2002Co-Authors: Jens Sydor, Steve Sideris, Maria Mariano, Steffen NockAbstract:Intein-mediated protein ligation is a recently developed method that enables the C-terminal labeling of proteins. This technique requires a correctly folded intein mutant that is fused to the C-terminus of a target protein to create a thioester, which allows the ligation of a peptide with an N-terminal cysteine (1, 2). Here we describe the establishment of this method for the labeling, under denaturing conditions, of target proteins that are expressed insolubly as intein fusion proteins. A GFPuv fusion protein with the Mycobacterium xenopi gyrA intein was expressed in inclusion bodies in Escherichia coli and initially used as a model protein to verify intein cleavage activity under different refolding conditions. The intein showed activity after refolding in nondenaturing and slightly denaturing conditions. A construct of the same intein with an anti-neutravidin single-chain antibody was also expressed in an insoluble form. The intein-mediated ligation was established for this single chain antibody-intein fusion protein under denaturing conditions in 4 M urea to prevent significant precipitation of the fusion protein during the first refolding step. Under optimized conditions, the single-chain antibody was labeled with a fluorescent peptide and used for antigen screening on a biochip after final refolding. This screening procedure allowed the determination of binding characteristics of the scFv for avidin proteins in a miniaturized format.
K. Mansinho - One of the best experts on this subject based on the ideXlab platform.
-
Coexistência de infeções oportunistas pulmonares num doente com infeção por vírus da imunodeficiência humana e uma forma persistente de pneumonia por Pneumocystis jirovecii: caso clínico
Elsevier, 2013Co-Authors: Ponces D. Bento, F. Esteves, O. Matos, A.c. Miranda, F. Ventura, C. Araújo, K. MansinhoAbstract:Resumo: Como é sabido, nos doentes com infeção por vírus da imunodeficiência humana (VIH) existe um alto risco de ocorrência de infeções oportunistas (IO), tais como as infeções por Pneumocystis jirovecii, um agente patogénico com distribuição mundial, que provoca pneumonia intersticial (PPc). Apresentamos um caso de um doente recém-diagnosticado com infeção por VIH-1 e múltiplas IO pulmonares, incluindo uma forma persistente de PPc, aspergilose invasiva (AI), e infeções por citomegalovírus e por Mycobacterium xenopi. Descrevemos a combinação de fatores cruciais para a recuperação do doente, que incluíram a obtenção de dados laboratoriais, intervenção cirúrgica e múltipla terapêutica antimicrobiana. Abstract: It is well established that HIV patients are at high risk of opportunistic infections (OI), like the ones caused by Pneumocystis jirovecii, a worldwide pathogen implicated in interstitial pneumonia (PcP). We present a case of a newly diagnosed HIV-1 patient with multiple OI, including a persistent form of PcP, an invasive aspergillosis (IA), cytomegalovirus and Mycobacterium xenopi lung infection. We describe the combination of laboratorial screening, surgery and antimicrobial therapy that were crucial for patient recovery. Palavras-chave: Vírus da imunodeficiência humana, Pneumonia por Pneumocystis jirovecii, Infeções oportunistas, Keywords: Human immunodeficiency virus, Pneumocystis jirovecii pneumonia, Opportunistic lung infection
